Rising cases of cancer and high incidence of
a number of metabolic diseases propel the global peptide therapeutics market.
Other industry drivers are prevalence of lifestyle diseases, introduction of
hybrid methods of peptides synthesis, growing global population, and improved
healthcare infrastructure. A molecule containing two or more amino acids is
known as a peptide. Therapeutic peptides are short amino acid monomer chains.
Peptides are commonly known as amide bonds.
These are used to treat blood-based disorders, certain types of cancers,
chronic ailments, CNS (central nervous system) disorders, and cardiovascular
& respiratory anomalies. Growing importance of peptide therapeutics in the
pharmaceutical market may significantly contribute to overall demand during the
forecast period (2012 to 2020). However, changing customer needs and lack of
regulatory standards hinder industry progress.
Browse Details of Report@https://www.hexaresearch.com/research-report/peptide-therapeutics-industry
The worldwide peptide therapeutics market is
categorized on the basis of technologies, applications, routes of
administration, products, and regions. Based on technologies, the segments are
HPPS (hybrid phase peptide synthesis), LPPS (liquid phase peptide synthesis),
and SPPS (solid phase peptide synthesis). Owing to cost effectiveness and
user-friendliness, SPPS was the largest contributor to the overall industry in
2013.On the basis of applications, the market is divided into respiratory,
cancer, anti-infection, pain, metabolic, cardiovascular, dermatology, renal,
gastro intestinal, and others. In 2013, peptide therapeutics were used extensively
in cancer treatment. High incidence of cancer cases worldwide is expected to
fuel this segment till 2020.
According to routes of administration, the
industry is segmented into mucosal, pulmonary, parenteral, oral, and others.
“Others” includes nasal and intradermal. Parenteral held the highest industry
share in 2013. Based on products, the bifurcations are generic and innovative.
Innovative peptides dominated the overall industry in 2013.
As per regions, the global peptide
therapeutics market is categorized into Europe, Asia Pacific, North America,
and Rest of the World. North America leads the global industry because of high
per capita expenditure on healthcare, rising income levels, and improvements in
healthcare infrastructure. The region receives substantial support from the
government and also from a number of NGOs.
Asia Pacific may witness robust growth over
the forecast period because of economic progress, favorable government
initiatives, and growing population. Japan, China, and India are the three key
regional drivers of the Asia Pacific market. Prominent companies operating in
the global peptide therapeutics market are Eli Lilly and Company; Takeda
Pharmaceutical Company Ltd.; Amylin Pharmaceuticals LLC; Bachem Holding AG; and
Teva Pharmaceuticals.
Rhythm, a U.S. based biopharmaceutical
company dealing in peptide therapeutics presented the phase 2 clinical trial
assessment of setmelanotide in November 2016. Setmelanotide, a peptide drug, is
the company’s melanocortin-4 receptor agonist that is generally used to treat
LepR (leptin receptor) deficiency obesity. This is a rare genetic anomaly that
leads to unrelenting hyperphagia and severe obesity. According to the company,
this disorder affects nearly two thousand people in the U.S. on an annual
basis.
Caused by deficiencies & defects in the
MC4 pathway, LepR deficiency obesity affects people in their early childhood.
The MC4 pathway in humans regulates appetite, energy expenditure, and
homeostasis. Setmelanotide’s efficacy was tested by researchers when it was
administered everyday by subcutaneous injection. Over a period of 22 weeks, a
LepR patient lost weight by almost 20%.
Browse Related
Category Market Reports @
About Us:
Hexa Research is a market research and
consulting organization, offering industry reports, custom research and
consulting services to a host of key industries across the globe. We offer
comprehensive business intelligence in the form of industry reports which help
our clients obtain clarity about their business environment and enable them to
undertake strategic growth initiatives.
Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Website - http://www.hexaresearch.com/
Visit Our Blog - hexaresearch1.blogspot.com
No comments:
Post a Comment